
Today, we’re speaking to Professor Miriam Santer, a GP in Dorset and Professor of Primary Care Research based at the University of Southampton.
Title of paper: Non-antibiotic interventions to prevent recurrent urinary tract infections in women: overview of systematic reviews of randomised controlled trials
DOI: https://doi.org/10.3399/BJGP.2026.0055
Recurrent urinary tract infection (UTI) is very common and defined as two or more UTIs in the last six months or three or more UTIs in the last 12 months. Long-term antibiotic prophylaxis is widely used but other preventative strategies have been suggested. This overview of systematic reviews found good evidence for some treatments but identified unresolved questions such as treatment adherence for vaginal oestrogen, questions about long-term use for methenamine hippurate and optimal dosage for cranberry. Increased fluid intake has been shown to be of benefit for women drinking less than 1.5 litres at baseline but is without robust evidence in other groups. The evidence base is still developing for other treatments, such as vaccines.
Transcript
This transcript was generated using AI and has not been reviewed for accuracy. Please be aware it may contain errors or omissions.
Speaker A
00:00:00.560 - 00:00:55.830
Hi and welcome today to BJJP interviews.
I'm Nada Khan and I'm the Senior Research editor for the bjgp.
In today's episode, we're talking to Professor Miriam Santer, a GP in Dorset and Professor of Primary care research based at the University of Southampton.
We're here to discuss the recent paper she's published here in the BJJP titled Non Antibiotic Interventions to Prevent Recurrent Urinary Tract Infections in Women.
An Overview of Systematic Reviews of Randomized Controlled Trials.
So, hi Miriam, it's nice to see you again.
And I suppose to start with, it's worth acknowledging that recurrent UTIs are something that we see incredibly often as GPs, but they can also have a really big impact on women's lives and I guess I just wanted to go through what prompted you to take this angle in this review and think about non antibiotic options for preventing them?
Speaker B
00:00:56.520 - 00:02:38.580
Well, it was exactly that, that I had a colleague, a non clinical colleague who had recurrent UTI and I guess I hadn't really appreciated the massive impact that they had in terms of, you know, keeping, being ill, keeping missing work, everything else.
And it did make me think again about my own practice, whether I really manage recurrent UTI or whether I just manage it as a series of one off events.
So it made me think about my own practice.
And then also the reason we looked at non antibiotic options was because the Primary Care Research Centre in Southampton where I work, we do a lot of work on infections and on antimicrobial stewardship and we were aware that prophylactic antibiotics tend to be quite well used and also series of one off antibiotic episodes are quite well used but that the non antibiotic interventions, we felt they were less well used and just wanted to know the evidence behind it.
Apart from doing infections research, we also do a lot of research on how to support people self manage long term conditions and we thought we could make a brilliant resource or online intervention to help people prevent urinary tract infection.
And as part of that we just wanted to know a bit more about the evidence based and in some ways we were a little disappointed that there wasn't much evidence for some of the very commonly advised things, but also surprised that for some things like methenamine and vaginal estrogen, actually the evidence base is, is pretty well established now.
So it was interesting.
Speaker A
00:02:38.900 - 00:03:04.080
Yeah.
And as you said, there's a huge number of things that women are told might help prevent recurrent UTIs and this was an umbrella review that brought together evidence from 27 systematic reviews.
But let's just talk through what.
So you mentioned about vaginal oestrogen, because this seems to be one of the clearest messages from the review.
Talk us through what you found and how strong is the evidence here?
Speaker B
00:03:04.480 - 00:04:07.360
So there were seven systematic reviews covering vaginal estrogen and they were pretty positive and especially the most recent one.
To be fair, most of the evidence is in post menopausal women, but the NICE guideline changed in 2024 to say perimenopausal and postmenopausal, because there's awareness in the rest of the menopause literature that actually genital urinary symptoms in menopause are often do present before menopause.
So it's a slightly confusing message.
The evidence base for prevention of UTIs is postmenopausal, but the guidelines are perimenopausal and postmenopausal.
But the evidence is pretty strong.
It's been amassing over a number of years.
Seven systematic reviews have been positive about it.
Unlike systemic oestrogen, where systematic reviews have been pretty conclusive that systemic estrogen doesn't make a difference in preventing recurrence.
But of course, women can take both at the same time if they need to.
Speaker A
00:04:07.520 - 00:04:21.750
And one thing I found really interesting was that there was particularly low uptake of vaginal estrogen in more deprived areas.
Do you think that there's something driving that and what can we do to try to prevent that sort of inequity in access?
Speaker B
00:04:21.990 - 00:05:59.500
And it's tempting to say more research needed.
And that was something we found in the literature, that there's a suggestion that vagina strings are less used in the UK than elsewhere.
They're less used in areas of greater socioeconomic deprivation.
And also it's not very well understood whether it's a prescribing issue or whether it's an uptake and adherence or acceptability issue.
There's.
So for prescribers, there's some things that are off putting.
So I don't really understand why vagina are not licensed for prevention of uti, given the evidence base for women.
It's a number of other things.
Sometimes, you know, not having had a sufficiently informed discussion about all the different types, you know, gel cream, pessaries, and sometimes it's also that the patient information leaflet that comes with the packet describes it as hrt, where it's really very little of it is systemically absorbed.
So it, it is, it's safer than hrt.
I mean, of course HRT is Pretty safe.
Vaginal estrogen is even safer.
But that message doesn't always get across.
And then also maybe it's because the information leaflet and all the other information tends to focus on genital urine symptoms of the menopause that people don't necessarily link it in their minds.
And I'm talking about prescribers as well as women with preventing UTI and maybe just don't keep using it long enough.
So more research needed.
But I think there's a number of barriers to uptake regarding vaginal estrogen and.
Speaker A
00:05:59.500 - 00:06:22.180
I can think of a lot of conversations I've had with women with recurrent UTIs and suggesting vaginal estrogen and often they're quite surprised but quite happy that I'm suggesting something that could work.
So I think there is a bit of a information asymmetry there between what some prescribers are doing, maybe people who are really used to prescribing these things and patients as well.
Speaker B
00:06:22.340 - 00:06:41.460
And I've also certainly met a few women who said, oh, was I meant to keep using that?
They don't necessarily see it as a, as something they need to take in the long term to keep preventing it, you know, which is.
And for something which you're only doing twice a week, that is a slightly challenging behavior to keep remembering to use it.
Speaker A
00:06:41.790 - 00:06:52.350
And I guess one other thing that you also found really good evidence for was methanomine.
Talk us through how we should be thinking about methanamine in relation to long term prophylaxis as well.
Speaker B
00:06:52.670 - 00:07:29.200
So methenamine has also made it into the nice guideline on preventing recurrent uti.
And I think I might have forgotten to say so that's anyone who's had two UTIs in six months or three UTIs in 12 months.
And the evidence is pretty good for methenamine as well as vaginase drinks.
As someone who hasn't responded to basic lifestyle advice, we might come on to that.
The evidence is a little bit poor, but it's still suggested that you discuss lifestyle advice first.
Should, if they're perimenopausal or menopausal, consider vaginal estrogen, but at all ages consider methenamine.
Speaker A
00:07:29.760 - 00:07:39.680
Interesting.
And do you think that I don't know if there's any evidence in these reviews about how they're used or whether they're underused or do you think gps are confident in prescribing these?
Speaker B
00:07:40.310 -...
Flere episoder fra "BJGP Interviews"



Gå ikke glip af nogen episoder af “BJGP Interviews” - abonnér på podcasten med gratisapp GetPodcast.








